Page 2 - Franka Damelio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Pfizer to Seek FDA Approval of COVID Jab for Kids 6 Months to 5 Years
breitbart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from breitbart.com Daily Mail and Mail on Sunday newspapers.
A Few Quick COVID Booster Updates
talkingpointsmemo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from talkingpointsmemo.com Daily Mail and Mail on Sunday newspapers.
Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
. (Tribune News Service) Before the coronavirus vaccines had even been proven to work, the United States scrambled to pre-order hundreds of millions of doses. The government has paid billions to Pfizer, Moderna and other vaccine makers so that every person in the country can get vaccinated free of charge. It doesn’t matter if you’re uninsured, undocumented, don’t have a regular doctor or a driver’s license. In the interest of taming the pandemic, the government did away with some of the biggest barriers people often face in accessing health care. Industry analysts and patient advocates are keeping a close eye on what happens next: If, once the federal health emergency has ended, the government stops bulk-buying the vaccine, costs could go up and people who are uninsured may be at risk of going without. Or perhaps the government’s approach to COVID-19 vaccination could lead the way to drug price reform that would allow federal programs, such as Medicare, to negotiate
Pfizer execs discuss hiking vaccine price after pandemic wanes By Audrey McNamara Pfizer and Moderna ramping up vaccine supplies
A top executive for Pfizer suggested to investors last week that pricing for its COVID-19 vaccine could increase post-pandemic. The suggestion raises questions about whether a drug, developed at the behest of the federal government to respond to a global crisis, could turn a profit for one company.
The possibility was raised by Carter Lewis Gould, a senior analyst for Biopharma Equity Research at Barclays, during a virtual global healthcare conference hosted by the bank. Gould, referencing comments made by Pfizer executives over the summer, asked how the pharmaceutical company still envisioned pursuing higher pricing as we move from a pandemic to an endemic phase, according to an edited transcript of the conversation.